[1]
StanisicS., BertolottoA., BertoP., Di ProcoloP. and MorawskiJ. 2019. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. Global & Regional Health Technology Assessment. 6, 1 (Apr. 2019). DOI:https://doi.org/10.33393/grhta.2019.465.